Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus

Clinical and Experimental Rheumatology

Volumn 32, Issue 1, 2014, Pages 48-53

  Li, Juan ^a,b   An, Lemei ^a   Zhang, Zhuoli ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b Department of Dermatology   (China)

Author keywords

Biomarker; C3d; C4d; Complement; Lymphocyte; Systemic lupus erythematosus

Indexed keywords

ADOLESCENT; ADULT; AGED; ANTIGENS, CD19; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CHI-SQUARE DISTRIBUTION; CHINA; COMPLEMENT ACTIVATION; COMPLEMENT C3D; COMPLEMENT C4B; FEMALE; FLOW CYTOMETRY; HUMANS; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84894071164     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. MOSCA M, TANI C, ARINGER M et al.: European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010; 69: 1269-74.
2. LLOYD W, SCHUR PH: Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine (Baltimore) 1981; 60: 208-17.
3. RICKER DM, HEBERT LA, ROHDE R, SEDMAK DD, LEWIS EJ, CLOUGH JD: Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosusactivity than are serum C4 levels. The Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 1991; 18: 678-85.
4. CHIMENTI MS, PERRICONE C, GRACEFFA D, et al.: Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. Clin Exp Rheumatol 2012; 30: 23-30.
5. WALZ LB, GLADMAN DD, UROWITZ MB: Serologically active clinically quiescent systemic lupus erythematosus - predictors of clinical flares. J Rheumatol 1994; 21: 2239-41.
6. ESDAILE JM, ABRAHAMOWICZ M, JOSEPH L, MacKENZIE T, LI Y, DANOFF D: Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum 1996; 39: 370-8.
7. GLADMAN DD, HIRANI N, IBANEZ D, UROWITZ MB: Clinically active serologically quiescent systemic lupus erythematosus. J Rheumatol 2003; 30: 1960-2.
8. REGGIA R, ZIGLIOLI T, ANDREOLI L, et al.: Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications?. Rheumatology (Oxford) 2012; 51: 2186-90.
9. BALLANTI E, PERRICONE C, GRECO E, et al.: Complement and autoimmunity. Immunol Res 2013; 56: 477-91.
10. SCHUR PH: Complement and lupus erythematosus. Arthritis Rheum 1982; 25: 793-8.
11. GATENBY PA: The role of complement in the aetiopathogenesis of systemic lupus erythematosus. Autoimmunity 1991; 11: 61-6.
12. SENALDI G, MAKINDE VA, VERGANI D, ISENBERG DA: Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus. Ann Rheum Dis 1988; 47: 913-7.
13. NEGI VS, AGGARWAL A, DAYAL R, NAIK S, MISRA R: Complement degradation product C3d in urine: marker of lupus nephritis. J Rheumatol 2000; 27: 380-3.
14. MANZI S, NAVRATIL JS, RUFFING MJ, et al.: Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3596-604.
15. KAO AH, NAVRATIL JS, RUFFING MJ, et al.: Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis Rheum 2010; 62: 837-44.
16. LIU CC, MANZI S, KAO AH, NAVRATIL JS, RUFFING MJ, AHEARN JM: Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus. Arthritis Rheum 2005; 52: 3087-99.
17. NAVRATIL JS, MANZI S, KAO AH, et al.: Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum 2006; 54: 670-4.
18. LIU CC, KAO AH, HAWKINS DM, et al.: Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus. Clin Transl Sci 2009; 2: 300-8.
19. TAN EM, COHEN AS, FRIES JF, et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
20. HOCHBERG MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
21. BOMBARDIER C, GLADMAN DD, UROWITZ MB, CARON D, CHANG CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-40.
22. ATKINSON JP, CHAN AC, KARP DR, et al.: Origin of the fourth component of complement related Chido and Rodgers blood group antigens. Complement 1988; 5: 65-76.
23. TILLEY CA, ROMANS DG, CROOKSTON MC: Localisation of Chido and Rodgers determinants to the C4d fragment of human C4. Nature 1978; 276: 713-5.
24. NICKELEIT V, MIHATSCH MJ: Kidney transplants, antibodies and rejection: is C4d a magic marker?. Nephrol Dial Transplant 2003; 18: 2232-9.
25. COHEN D, COLVIN RB, DAHA MR, et al.: Pros and cons for C4d as a biomarker. Kidney Int 2012; 81: 628-39.
26. KALUNIAN KC, CHATHAM WW, MASSAROTTI EM, et al.: Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis Rheum 2012; 64: 4040-7.